Thrombinar, Thrombostat
Classifications: coagulator, hemostatic, topical;
Therapeutic: coagulator
; hemostatic
Prototype: Aminocaproic acid
Pregnancy Category: C


1000, 5000, 10,000, 20,000, 50,000 unit vials


Plasma protein prepared from prothrombin of bovine origin. Induces clotting of whole blood or fibrinogen solution without addition of other substances.

Therapeutic Effect

Facilitates conversion of fibrinogen to fibrin resulting in clotting of whole blood.


When oozing of blood from capillaries and small venules is accessible, as in dental extraction, plastic surgery, grafting procedures, and epistaxis; also to shorten bleeding time at puncture sites in heparinized patient (i.e., following hemodialysis).


Known hypersensitivity to any of drug components or to material of bovine origin; parenteral use; entry or infiltration into large blood vessels; pregnancy (category C).

Cautious Use

Children and infants.

Route & Dosage

Oozing Blood
Adult: Topical 100–2000 NIH U/mL, depending on extent of bleeding, may be used as solution, in dry form, by mixing thrombin with blood plasma to form a fibrin "glue," or in conjunction with absorbable gelatin sponge


  • Ensure that sponge recipient area is free of blood before applying thrombin.
  • Prepare solutions in sterile distilled water or isotonic saline.
  • Use solutions within a few hours of preparation. If several hours are to elapse between time of preparation and use, solution should be refrigerated, or preferably frozen, and used within 48 h.
  • Store lyophilized preparation at 2°–8° C (36°–46° F).

Adverse Effects (≥1%)

Body as a Whole: Sensitivity, allergic and febrile reactions, intravascular clotting and death when thrombin is allowed to enter large blood vessels.

Common adverse effects in italic, life-threatening effects underlined; generic names in bold; classifications in SMALL CAPS; Canadian drug name; Prototype drug

© 2006-2022 Last Updated On: 11/24/2022 (0.02)
Wait 20 seconds...!!!